Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corporation (Nasdaq: LFVN) is a health and wellness company centered on nutrigenomics and cellular activation, and its news flow reflects this focus. The company regularly issues updates on its activator-based product portfolio, consultant community, scientific research, and participation in investor and industry events. As the Activation company, LifeVantage highlights how its products, such as the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, and the comprehensive gut activator P84, fit into broader wellness systems and scientific narratives.
News about LifeVantage often covers new product launches and enhancements, including additions to its activation-supporting nutrients, AXIO nootropic energy drink mixes, and TrueScience skin and hair care line. Company communications also describe major field events like Momentum Academy and Global Kickoff, where Consultants receive training, hear about new tools, and learn strategies related to enrollment, retention, and advancement. These events frequently coincide with the introduction of new offerings or the integration of acquired product lines such as LoveBiome’s P84.
Investors following LFVN can also expect announcements on quarterly and annual financial results, dividend declarations, share repurchase activity, and guidance ranges, as well as notices of participation in conferences and fireside chats. The company’s releases include commentary from management on strategic initiatives such as integrating LoveBiome assets, expanding its wellness ecosystem, and advancing digital capabilities like the Daily Activation app.
This news page aggregates these updates so readers can track developments in LifeVantage’s product science, consultant network, and corporate strategy in one place. For anyone monitoring LFVN stock, the consultant-driven business model, or trends in nutrigenomics-focused wellness products, the news feed provides an ongoing view of how the company communicates its progress and priorities.
LifeVantage Corporation (Nasdaq: LFVN) reported Q2 fiscal 2022 results, with revenue of $52.2 million, down 11.6% YoY and 1.9% sequentially. Active accounts fell 6.3% to 163,000, driven by a 17.1% drop in the Americas. Earnings per diluted share were $0.01, compared to $0.26 last year, while adjusted EBITDA decreased 71.6% to $1.9 million. The company repurchased 0.5 million shares for $3.2 million and ended the quarter with $20.2 million in cash and no debt. Guidance for fiscal 2022 has been lowered, anticipating revenues of $212-$220 million.
LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the second quarter ended December 31, 2021, on February 1, 2022, post-market close. A conference call for investors is scheduled for 2:30 PM MT (4:30 PM ET) the same day. Interested participants can join by dialing (877) 705-6003 or (201) 493-6725 for international callers. A replay will be available shortly after the call until February 8, 2022. LifeVantage focuses on nutrigenomics, offering products like Protandim® and Petandim®, with an emphasis on health and wellness.
LifeVantage Corporation (Nasdaq: LFVN) announced its participation in the 2022 ICR Conference on January 10 at 9:30 a.m. Eastern Time. The presentation will be accessible via a live webcast on the company's Investor Relations website.
LifeVantage specializes in nutrigenomics, focusing on how nutrition impacts health. Their product range includes dietary supplements, nootropics, and skincare. Notable products include the Protandim® family and the Axio® energy drink. For more details, visit the company's website.
LifeVantage Corporation (NASDAQ:LFVN) has launched its business in the Philippines through its subsidiary, Protandim Philippines Corporation, marking a significant step in its global expansion. The company aims to introduce wellness products, including its flagship Protandim® Nrf2 Synergizer®, to the Filipino market. LifeVantage now operates in over 20 countries and offers more than 40 health and wellness products. The CEO emphasized the company's commitment to the Filipino community and its goal of assisting individuals in creating a personal legacy.
LifeVantage Corporation (Nasdaq: LFVN) reported Q1 FY2022 results with revenue of $53.2 million, reflecting a 2.9% year-over-year decline. Active accounts dropped 4.7% to 164,000, mainly due to a 9.4% decrease in the Americas. Earnings per diluted share rose to $0.25, up 47.1%. Adjusted EBITDA decreased 13.7% to $5.8 million. The company anticipates revenue between $225 million to $235 million for FY2022 and adjusted earnings per share of $0.83 to $0.87, factoring in COVID-19 impacts.
LifeVantage Corporation (Nasdaq:LFVN) has appointed Carl Aure as its new Chief Financial Officer, effective October 25, 2021. With over 24 years in finance and accounting, Aure has significant experience in the direct selling industry, including his previous role as Chief Accounting Officer at New Age, Inc. His expertise in finance, accounting, and mergers & acquisitions is seen as crucial for LifeVantage's growth strategy. Aure expressed enthusiasm about joining the company, which specializes in nutrigenomics and aims to accelerate its growth through innovative product offerings.
LifeVantage Corporation (Nasdaq:LFVN) will release its first-quarter financial results for the period ending September 30, 2021, on November 4, 2021, after market close. A conference call for investors is scheduled for 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested participants can join via phone or through a live webcast available on the company's Investor Relations website. LifeVantage specializes in nutrigenomics and offers a range of dietary supplements and health products aimed at improving human health.
LifeVantage Corporation (Nasdaq: LFVN) announced a five-year donation commitment to the Linus Pauling Institute (LPI) at Oregon State University, contributing to the LPI Research Innovation Fund. This partnership aims to enhance health through nutrition research. Senior VP Dr. Brian Dixon will join LPI's Director’s Circle, providing strategic insight. The collaboration allows LifeVantage to access third-party research and engage with leading researchers, aligning both organizations' goals of optimizing health through innovative nutrition.
LifeVantage Corporation (Nasdaq: LFVN) announced its fourth quarter and full year financial results for fiscal 2021, reporting revenue of $220.2 million, a 5.5% decline from the previous year. The fourth quarter revenue reached $54.8 million, down 7.7% year-over-year but up 6.2% sequentially. Adjusted EPS for Q4 was $0.31, up 10.7%. The company repurchased 1.2 million shares for $11.9 million and has a solid balance sheet with $23.2 million in cash and no debt. Guidance for fiscal 2022 forecasts revenue between $225 million and $235 million.
LifeVantage Corporation (Nasdaq: LFVN) is set to announce its financial results for Q4 and full fiscal year ending June 30, 2021, on August 19, 2021, after market close. A conference call with investors will follow at 2:30 p.m. MT. Interested parties can join by calling (877) 705-6003 for U.S. participants or (201) 493-6725 internationally. A replay of the call will be available until August 26, 2021. The company specializes in nutrigenomics and offers a range of health products, including dietary supplements and skincare lines.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
